Tarsus Pharmaceuticals In...

AI Score

XX

Unlock

49.25
-0.14 (-0.28%)
At close: Apr 17, 2025, 3:59 PM
49.03
-0.45%
After-hours: Apr 17, 2025, 06:09 PM EDT
-0.28%
Bid 45
Market Cap 2.05B
Revenue (ttm) 182.95M
Net Income (ttm) -115.55M
EPS (ttm) -3.07
PE Ratio (ttm) -16.04
Forward PE 39.65
Analyst Buy
Ask 51.11
Volume 335,501
Avg. Volume (20D) 626,314
Open 49.13
Previous Close 49.39
Day's Range 48.69 - 50.32
52-Week Range 20.08 - 57.28
Beta 0.94

About TARS

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; a...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 323
Stock Exchange NASDAQ
Ticker Symbol TARS
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for TARS stock is "Buy." The 12-month stock price forecast is $66, which is an increase of 34.01% from the latest price.

Stock Forecasts

Next Earnings Release

Tarsus Pharmaceuticals Inc. is scheduled to release its earnings on May 7, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-9.33%
Shares of Tarsus Pharmaceuticals are trading lower... Unlock content with Pro Subscription
5 months ago
+0.3%
Tarsus Pharmaceuticals shares are trading higher after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $63 to $65.